Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
L36, 1 Macquarie Place, Sydney, NSW, 2000
+61 2 8051 3043
Get the latest news and updates